Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
Home โบ Stocks โบ Hyperion DeFi, Inc. (EYEN) Stock Forecast & Price Prediction United States | NASDAQ | Healthcare | Biotechnology
$2.93
-0.06 (-2.01%)Did EYEN Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Eyenovia is one of their latest high-conviction picks.
EYEN has shown a year-to-date change of -17.7% and a 1-year change of -1.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for EYEN. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for EYEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Nov 18, 2024 | Ladenburg Thalmann | Matthew Kaplan | Neutral | Downgrade | $N/A |
| Nov 18, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| Nov 15, 2024 | William Blair | Tim Lugo | Market Perform | Downgrade | $N/A |
| Nov 15, 2024 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $N/A |
| Nov 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Jul 24, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 16, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 19, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 14, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Nov 1, 2023 | William Blair | Tim Lugo | Outperform | Initiates | $N/A |
| Oct 17, 2023 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $8.00 |
| Aug 18, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| May 12, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 19, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Apr 3, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
The following stocks are similar to Eyenovia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hyperion DeFi, Inc. has a market capitalization of $14.96M with a P/E ratio of 0.0x. The company generates $57,336 in trailing twelve-month revenue with a -6,749.5% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -82,555.5% and return on equity of +380.4%.
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Integrates decentralized finance with digital assets.
The company generates revenue by managing a strategic treasury focused on the HYPE token, accumulating and staking these tokens through proprietary validators to earn on-chain yield. It also seeks partnerships that provide institutional access to compliant liquid staking and on-chain trading strategies, facilitating a bridge between traditional finance and DeFi.
Hyperion DeFi, Inc. is the first publicly listed U.S. firm adopting a DeFi-centric approach, allowing shareholder exposure to digital assets while maintaining interests in ophthalmic technology. This unique positioning underscores its role as a pioneer in merging traditional markets with blockchain finance.
Healthcare
Biotechnology
9
Mr. Hyunsu Jung
United States
2018
Eyenovia's shares surged over 100% following a $50 million investment agreement and plans for a hyperliquid cryptocurrency treasury reserve strategy.
Eyenovia's share surge indicates strong investor confidence following a significant investment and innovative cryptocurrency strategy, suggesting potential for growth and increased market interest.
Eyenovia, Inc. (NASDAQ: EYEN) announced a $50 million private placement with institutional investors and appointed Hyunsu Jung as Chief Investment Officer and Board Member.
Eyenovia's $50 million PIPE financing indicates strong institutional interest and positions the company as a pioneer in holding HYPE, potentially enhancing its market appeal and valuation.
EYEN is recruiting a key figure from Hyperliquid to enhance its HYPE Treasury Strategy, indicating a strategic move to strengthen financial management.
The appointment of a prominent thought leader for HYPE Treasury Strategy signals potential strategic advancements for EYEN, which may enhance its market positioning and investor confidence.
Chardan has expanded into the digital asset sector, advising on transactions connecting traditional markets with blockchain. They acted as placement agent for Eyenovia's $50M PIPE financing.
Chardan's expansion into digital assets signals growing institutional interest in crypto, potentially increasing market legitimacy and attracting more investment to blockchain initiatives.
Eyenovia and Betaliq are negotiating a binding merger agreement, following the previously signed Letter of Intent.
The ongoing merger negotiations between Eyenovia and Betaliq could impact stock prices, market position, and future growth potential, influencing investor sentiment and investment decisions.
The company plans to submit for marketing approval of the Optejet UFD in Q4 2025.
The upcoming regulatory submission for the Optejet UFD signals potential revenue growth and market expansion, impacting the company's valuation and stock performance.
Analyst forecasts for Hyperion DeFi, Inc. (EYEN) are not currently available. The stock is trading at $2.93.
According to current analyst ratings, EYEN has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.93. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for EYEN are not currently available. The stock is trading at $2.93.
The company generates revenue by managing a strategic treasury focused on the HYPE token, accumulating and staking these tokens through proprietary validators to earn on-chain yield. It also seeks partnerships that provide institutional access to compliant liquid staking and on-chain trading strategies, facilitating a bridge between traditional finance and DeFi.
Price targets from Wall Street analysts for EYEN are not currently available. The stock is trading at $2.93.
Price targets from Wall Street analysts for EYEN are not currently available. The stock is trading at $2.93.
The overall analyst consensus for EYEN is neutral. Out of 6 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
Stock price projections, including those for Hyperion DeFi, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.